IBDEI06Y ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,3075,1,4,0)
 ;;=4^396.8
 ;;^UTILITY(U,$J,358.3,3075,1,5,0)
 ;;=5^AORTIC/MITRAL STENOSIS/REGURG
 ;;^UTILITY(U,$J,358.3,3075,2)
 ;;=^269584
 ;;^UTILITY(U,$J,358.3,3076,0)
 ;;=414.00^^33^271^17
 ;;^UTILITY(U,$J,358.3,3076,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3076,1,4,0)
 ;;=4^414.00
 ;;^UTILITY(U,$J,358.3,3076,1,5,0)
 ;;=5^CAD
 ;;^UTILITY(U,$J,358.3,3076,2)
 ;;=^28512
 ;;^UTILITY(U,$J,358.3,3077,0)
 ;;=425.4^^33^271^20
 ;;^UTILITY(U,$J,358.3,3077,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3077,1,4,0)
 ;;=4^425.4
 ;;^UTILITY(U,$J,358.3,3077,1,5,0)
 ;;=5^CARDIOMYOPATHY
 ;;^UTILITY(U,$J,358.3,3077,2)
 ;;=^87808
 ;;^UTILITY(U,$J,358.3,3078,0)
 ;;=410.90^^33^271^61
 ;;^UTILITY(U,$J,358.3,3078,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3078,1,4,0)
 ;;=4^410.90
 ;;^UTILITY(U,$J,358.3,3078,1,5,0)
 ;;=5^MYOCARDIAL INFARCTION
 ;;^UTILITY(U,$J,358.3,3078,2)
 ;;=^269673
 ;;^UTILITY(U,$J,358.3,3079,0)
 ;;=427.2^^33^271^66
 ;;^UTILITY(U,$J,358.3,3079,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3079,1,4,0)
 ;;=4^427.2
 ;;^UTILITY(U,$J,358.3,3079,1,5,0)
 ;;=5^PAROX ATR TACHYCARDIA
 ;;^UTILITY(U,$J,358.3,3079,2)
 ;;=^117073
 ;;^UTILITY(U,$J,358.3,3080,0)
 ;;=272.4^^33^271^57
 ;;^UTILITY(U,$J,358.3,3080,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3080,1,4,0)
 ;;=4^272.4
 ;;^UTILITY(U,$J,358.3,3080,1,5,0)
 ;;=5^Hyperlipidemia, NOS
 ;;^UTILITY(U,$J,358.3,3080,2)
 ;;=^87281
 ;;^UTILITY(U,$J,358.3,3081,0)
 ;;=271.3^^33^272^11
 ;;^UTILITY(U,$J,358.3,3081,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3081,1,4,0)
 ;;=4^271.3
 ;;^UTILITY(U,$J,358.3,3081,1,5,0)
 ;;=5^Glucose Intolerance
 ;;^UTILITY(U,$J,358.3,3081,2)
 ;;=^64790
 ;;^UTILITY(U,$J,358.3,3082,0)
 ;;=611.1^^33^272^16
 ;;^UTILITY(U,$J,358.3,3082,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3082,1,4,0)
 ;;=4^611.1
 ;;^UTILITY(U,$J,358.3,3082,1,5,0)
 ;;=5^Gynecomastia
 ;;^UTILITY(U,$J,358.3,3082,2)
 ;;=^60454
 ;;^UTILITY(U,$J,358.3,3083,0)
 ;;=704.1^^33^272^17
 ;;^UTILITY(U,$J,358.3,3083,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3083,1,4,0)
 ;;=4^704.1
 ;;^UTILITY(U,$J,358.3,3083,1,5,0)
 ;;=5^Hirsutism
 ;;^UTILITY(U,$J,358.3,3083,2)
 ;;=^57407
 ;;^UTILITY(U,$J,358.3,3084,0)
 ;;=251.2^^33^272^27
 ;;^UTILITY(U,$J,358.3,3084,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3084,1,4,0)
 ;;=4^251.2
 ;;^UTILITY(U,$J,358.3,3084,1,5,0)
 ;;=5^Hypoglycemia NOS
 ;;^UTILITY(U,$J,358.3,3084,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,3085,0)
 ;;=257.2^^33^272^28
 ;;^UTILITY(U,$J,358.3,3085,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3085,1,4,0)
 ;;=4^257.2
 ;;^UTILITY(U,$J,358.3,3085,1,5,0)
 ;;=5^Hypogonadism,Male
 ;;^UTILITY(U,$J,358.3,3085,2)
 ;;=^88213
 ;;^UTILITY(U,$J,358.3,3086,0)
 ;;=253.2^^33^272^31
 ;;^UTILITY(U,$J,358.3,3086,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3086,1,4,0)
 ;;=4^253.2
 ;;^UTILITY(U,$J,358.3,3086,1,5,0)
 ;;=5^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,3086,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,3087,0)
 ;;=733.00^^33^272^40
 ;;^UTILITY(U,$J,358.3,3087,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3087,1,4,0)
 ;;=4^733.00
 ;;^UTILITY(U,$J,358.3,3087,1,5,0)
 ;;=5^Osteoporosis NOS
 ;;^UTILITY(U,$J,358.3,3087,2)
 ;;=^87159
 ;;^UTILITY(U,$J,358.3,3088,0)
 ;;=278.00^^33^272^37
 ;;^UTILITY(U,$J,358.3,3088,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3088,1,4,0)
 ;;=4^278.00
 ;;^UTILITY(U,$J,358.3,3088,1,5,0)
 ;;=5^Obesity
 ;;^UTILITY(U,$J,358.3,3088,2)
 ;;=^84823
 ;;^UTILITY(U,$J,358.3,3089,0)
 ;;=278.01^^33^272^36
 ;;^UTILITY(U,$J,358.3,3089,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3089,1,4,0)
 ;;=4^278.01
 ;;^UTILITY(U,$J,358.3,3089,1,5,0)
 ;;=5^Morbid Obesity
